Curexsys researchers contribute to two studies that will be presented at the annual meeting of the European Society for Cell and Gene Therapy (ESGCT 2021). Both have been performed in cooperation with the Advanced Therapies Unit, Instituto Distrital de Ciencia Biotecnología e Innovación en Salud (IDCBIS), Bogotá, Colombia and investigate the potential of mesenchymal stroma/stem cells (MSCs) in therapeutic use.

One project (entitled: Engineered human neonatal mesenchymal stromal cells expressing FGFb: assessment of immunophenotype, proliferation, differentiation and immunosuppressive effects in vitro) involved genetic engineering of MSCs by lentiviral transduction and effects of expression of basic fibroblast growth factor (bFGF).

The second study (entitled: Differentially expressed miRNAs in human Wharton’s Jelly mesenchymal stromal cells-derived extracellular vesicles: revealing potential mechanisms of action in immune modulation) introduces transcriptome analyses and the effects of gene regulatory RNAs in extracellular vesicles on immunomodulation, a key-prerequisite of the regenerative and therapeutic function of MSCs.